allergen immunotherapy control-Johns Hopkins University-perennial allergic rhinitis

Allergen Immunotherapy Control (Johns Hopkins University) refers to the placebo comparator arm used in the Phase 2 clinical trial NCT03360071. This randomized, double-blind study was conducted by Johns Hopkins University to evaluate the efficacy and safety of a novel subcutaneous multiallergen immunotherapy (PMA) for the management of moderate to severe perennial allergic rhinitis. The control solution was administered via bi-weekly subcutaneous injections over an 8-week period to serve as a baseline for comparison against the active treatment, which contained a mixture of over 150 aeroallergens. As a placebo, this intervention lacks active allergenic components and is intended to account for the placebo effect and the physical impact of the injection procedure during the clinical evaluation.

Other names

Allergen Immunotherapy Control Solution